Analysts spread the love as Biogen Idec excites on MS, Alzheimer's

Analysts like to take an early front-row seat on a hot biotech company likely to please the market with a looming set of data. So, as Biogen Idec's ($BIIB) R&D chief Doug Williams already primed expectations earlier with his remarks on promising results seen in early-stage results for its Alzheimer's drug BIIB037, tomorrow's big reveal has focused a bright beam of attention on the company. Credit Suisse analyst Ravi Mehrotra is amped up about 037 as well as anti-LINGO, which is exploring a new approach to repairing the damage that causes multiple sclerosis. He sees each of these drugs as potential blockbusters able to amass more than $5 billion a year in peak sales. And that has quite a few analysts predicting that the company's shares, which have been steaming ahead, are set for another hike. Story

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.